Carlos Caldas

FMedSci
Born
Carlos Manuel Simão da Silva Caldas

27 June 1960
Alma materUniversity of Lisbon Medical School
AwardsFellow of the Academy of Medical Sciences
Scientific career
InstitutionsCancer Research UK Cambridge Institute, University of Cambridge Addenbrooke's Hospital
Robinson College, Cambridge
Websitewww.cruk.cam.ac.uk/research-groups/caldas-group

Professor Carlos Caldas FMedSci is a clinician scientist and Senior Group Leader at the Cancer Research UK Cambridge Institute, University of Cambridge. He is the Chair of Cancer Medicine at the University of Cambridge, an Honorary Consultant Medical Oncologist at Addenbrooke's Hospital and Director of the Cambridge Breast Cancer Research Unit.[1][2] He is a fellow of Robinson College, Cambridge[3] and an Emeritus Senior Investigator at the National Institute for Health Research (NIHR).[4]

Education

Professor Carlos Caldas graduated from the University of Lisbon Medical School before training in Internal Medicine in University of Texas Southwestern, Dallas and Medical Oncology at Johns Hopkins Hospital, Baltimore. He then moved to the Institute of Cancer Research, London to complete a research fellowship.[1]

Research and career

Caldas' research focuses on the functional genomics of breast cancer.[5][6] Caldas led the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study, analysing the genome and transcriptome of tumours from nearly 2,000 women and comparing this with long-term clinical information including survival, age and diagnosis. The METABRIC study concluded that breast cancer was at least ten different subtypes, characterised by distinct genomic drivers.[7][8] In 2019, the team published research showing the subtype a women's breast cancer is initially placed in could predict the likelihood of the tumour returning or metastasising over the next 20 years.[9][10][11]

Professor Caldas leads the Personalised Breast Cancer Programme in Cambridge, where woman diagnosed with breast cancer have a sample of their tumour and blood sent for DNA and RNA sequencing. The sequencing results help determine the best course of treatment for patients and can reveal if their tumour is developing resistance to treatment.[12][13][14]

Awards and honours

References

  1. 1 2 "Prof C Caldas | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-08-29.
  2. ↑ kla29@cam.ac.uk. "Professor Carlos Caldas — Department of Oncology". www.oncology.cam.ac.uk. Retrieved 2019-08-29.{{cite web}}: CS1 maint: numeric names: authors list (link)
  3. ↑ Caldas's Robinson College webpage
  4. ↑ "NIHR Senior Investigators 2020". NIHR. Retrieved 2022-02-09.
  5. ↑ "Carlos Caldas - Google Scholar Citations". scholar.google.co.uk. Retrieved 2019-08-29.
  6. ↑ "Caldas Group". Cancer Research UK Cambridge Institute. Retrieved 2019-08-29.
  7. ↑ Aparicio, Samuel; Caldas, Carlos; Tavaré, Simon; Brenton, James D.; Børresen-Dale, Anne-Lise; Purushotham, Arnie; Ellis, Ian; Murphy, Leigh; Markowetz, Florian (June 2012). "The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups". Nature. 486 (7403): 346–352. Bibcode:2012Natur.486..346.. doi:10.1038/nature10983. ISSN 1476-4687. PMC 3440846. PMID 22522925.
  8. ↑ Gallagher, James (2012-04-18). "Breast cancer map 'a key moment'". Retrieved 2019-08-29.
  9. ↑ Curtis, Christina; Caldas, Carlos; Aparicio, Samuel; Rueda, Cristina; Pharoah, Paul D.; Ellis, Ian O.; Purushotham, Arnie; Murphy, Leigh; Green, Andrew R. (March 2019). "Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups". Nature. 567 (7748): 399–404. Bibcode:2019Natur.567..399R. doi:10.1038/s41586-019-1007-8. ISSN 1476-4687. PMC 6647838. PMID 30867590.
  10. ↑ Gallagher, James (2019-03-14). "Cancer's 'internal wiring' predicts relapse risk". Retrieved 2019-08-29.
  11. ↑ "Breast cancer test could predict chances of disease's return 20 years later, study shows". The Independent. 2019-03-13. Retrieved 2019-08-29.
  12. ↑ Walsh, Fergus (2018-06-27). "DNA 'barcode' can transform cancer care". Retrieved 2019-08-29.
  13. ↑ Pilgrim, Tom (2018-07-23). "Breast cancer DNA 'barcoding' programme set to expand". cambridgenews. Retrieved 2019-08-29.
  14. ↑ "PBCP study takes breast cancer research to the next level in the development of personalised cancer medicine | Cambridge University Hospitals". www.cuh.nhs.uk. Retrieved 2019-08-29.
  15. ↑ "Professor Carlos Caldas | The Academy of Medical Sciences". acmedsci.ac.uk. Retrieved 2019-08-29.
  16. ↑ "Fellows| European Academy of Cancer Sciences". www.europeancanceracademy.eu. Archived from the original on 2019-07-04. Retrieved 2019-08-29.
  17. ↑ "Find people in the EMBO Communities". people.embo.org. Retrieved 2019-08-29.
  18. ↑ "Three Group Leaders elected to EMBO Membership". Cancer Research UK Cambridge Institute. 2015-05-20. Retrieved 2019-08-29.
  19. ↑ "Press Release: ESMO Recognises Carlos Caldas with Hamilton Fairley Award | ESMO". www.esmo.org. Retrieved 2019-08-29.
  20. ↑ "ESHG Award | ESHG". www.eshg.org. Retrieved 2021-03-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.